Triclabendazole

(Egaten®)

Triclabendazole

Drug updated on 12/11/2024

Dosage FormTablet (oral; 250 mg)
Drug ClassAntihelmintics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of fascioliasis in patients 6 years of age and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one randomized controlled trial. [1]
  • The study does not provide data on the effectiveness of triclabendazole in treating human fascioliasis.
  • The study population consisted of 45 healthy participants, with no reported subgroup analyses or outcomes specific to effectiveness.
  • Triclabendazole showed a mean placebo-corrected QTcF prolongation of 9.2 ms at the therapeutic dose and 21.7 ms at the supratherapeutic dose, with the upper limit of the two-sided 90% confidence interval exceeding 10 ms at most timepoints, indicating a potential effect on cardiac repolarization.
  • No deaths, serious adverse events, study discontinuations, or clinically relevant abnormalities in laboratory evaluations and vital signs were observed in the 45 healthy participants.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Egaten (triclabendazole) Prescribing Information.2022Novartis Pharmaceuticals Corporation, East Hanover, NJ

Randomized Controlled Trials